Cleveland Clinic Journal of Medicine
- Does my patient have testosterone deficiency?
Diagnosis of testosterone deficiency requires the presence of relevant signs or symptoms along with biochemical evidence.
- Diagnosis and management of pancreatic cystic lesions for the non-gastroenterologist
A summary of current guidelines from several organizations on the diagnosis and surveillance of pancreatic cystic lesions.
- It’s a new year, looking back and looking forward
Reflections on highlights from 2023 and impending changes in 2024, along with some acknowledgments and farewells.
- Conjunctival petechiae in infective endocarditis
A 75-year-old-man presented with a 33-day history of intermittent nocturnal fevers of 39°C (102°F) and truncal rashes. The rashes appeared on the same day as the fever.
- Consumer-grade wearable cardiac monitors: What they do well, and what needs work
The authors review common consumer-grade wearables, including the accuracy of these monitors compared with medical-grade devices, and present an approach to managing rate or rhythm abnormalities identified on at-home monitoring.
- Wearable cardiac monitors: Where do we stand?
Wearable monitors perform well as screening tools for atrial fibrillation, but questions remain: Can they help with stroke prevention, what is their role in patients with known atrial fibrillation, and how do we streamline interpretation?
- Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting
Malignancy develops in only a small minority of patients with gastric intestinal metaplasia. Recognition of clinical, endoscopic, and histologic features linked with cancer development is critical to identifying patients who require endoscopic surveillance.
- 2023 Update in ambulatory general internal medicine
Topics reviewed include prevention of chronic kidney disease progression, diet for preventing secondary cardiovascular disease, prevention of kidney-stone recurrence, drug therapy for weight loss, and cholesterol management.
- When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
Evidence from clinical trials supports starting these medications as early as possible in patients hospitalized with acute decompensated heart failure who do not have clear contraindications to them.